Preformed donor‐specific antibodies do not affect the 1‐year allograft survival in living donor liver transplantation
- 26 March 2018
- journal article
- research article
- Published by Wiley in Clinical Transplantation
- Vol. 32 (5) , e13244
Abstract
The effect of preformed donor‐specific antibodies (DSAs) on liver transplantation (LT) remains unclear, especially in the field of living donorLT(LDLT). Herein, we evaluated the prevalence of preformedDSAs and their effect on graft outcome inLDLTin the first year following surgery. Using the Luminex®Single Antigen assay, we analyzed the preoperative sera of 61 adultLDLTrecipients between 2014 and 2015. Clinical outcomes and pathologic findings including complement component 4d (C4d) expression in the first year afterLTwere retrospectively reviewed. Regardless of the class ofDSA,DSAs with mean fluorescence intensity (MFI) ≥1000 were defined as positive and preformedDSAwithMFI≥5000 was defined as strongly positive. Fifteen patients (24.6%) had preformedDSAs, and 8 patients (13.1%) showed strongly positive preformedDSAs. Among 15DSApositive patients, 2 (13.3%) showed persistentDSAs afterLDLT. No de novoDSAs were noted in patients without preformedDSAs. PreformedDSAs were not related to graft dysfunction, laboratory values, or C4d expression or other pathologic findings in the first year ofLDLT. In conclusion, preformedDSAs persisted during follow‐up in 13.3% of cases and did not have adverse effect on histologic or clinical outcomes in the first year ofLDLT.Keywords
Funding Information
- Korean Society for Transplantation
This publication has 36 references indexed in Scilit:
- Clinical significance of donor-specific human leukocyte antigen antibodies in liver transplantationWorld Journal of Gastroenterology, 2015
- Antibody-mediated rejection in liver transplantation: Current controversies and future directionsLiver Transplantation, 2014
- Histologically proven non‐alcoholic fatty liver disease and clinically related factors in recipients after liver transplantationClinical Transplantation, 2014
- Preoperative Selective Desensitization of Live Donor Liver Transplant Recipients Considering the Degree of T Lymphocyte Cross-Match Titer, Model for End-Stage Liver Disease Score, and Graft Liver VolumeJournal of Korean Medical Science, 2014
- Antibody-Mediated Rejection as a Contributor to Previously Unexplained Early Liver Allograft LossLiver Transplantation, 2013
- Pretransplant donor-specific anti-HLA antibodies as predictors of early allograft rejection in ABO-compatible liver transplantationLiver Transplantation, 2013
- Liver allograft antibody-mediated rejection with demonstration of sinusoidal C4d staining and circulating donor-specific antibodiesLiver Transplantation, 2010
- Does a positive lymphocyte cross-match contraindicate living-donor liver transplantation?Surgery, 2010
- Preformed Antibodies Detected by Cytotoxic Assay or Multibead Array Decrease Liver Allograft Survival: Role of Human Leukocyte Antigen CompatibilityLiver Transplantation, 2008
- Significance of positive cytotoxic cross-match in adult-to-adult living donor liver transplantation using small graft volumeLiver Transplantation, 2002